South Korean company buys CDMO AMPAC

This plant in Petersburg, Virginia, is one of four that South Korea's SK Holdings has acquired in a deal to buy CDMO AMPAC. (SK Holdings)

South Korean investment firm SK Holdings got a start in contract manufacturing last year by snatching up a discarded Big Pharma plant in Europe. Now it has made a move on the U.S. with a deal to buy AMPAC, a contract manufacturer which makes APIs for controlled substances, among other things.

The two companies announced the deal on Thursday but not the terms. SK said the acquisition gives it not only a U.S. base but also a well-positioned U.S. manufacturing network with facilities on three coasts. AMPAC Fine Chemicals (AFC) has plants in Rancho Cordova and El Dorado Hills, California; La Porte, Texas; and Petersburg, Virginia.

"AFC's development and manufacturing capabilities and outstanding regulatory track record, evidenced by the fact that the California plant is utilized by the FDA as a training site, are an excellent complement to SK," CEO Dong-Hyun Jang said in a statement.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Last year, SK Biotek celebrated being the first South Korean drug company to set up operations in Ireland at the API plant in Swords it acquired from Bristol-Myers Squibb. It took over the 360 employees who worked there and got a contract to continue to produce some products for Bristol-Myers.

RELATED: Bristol-Myers selling Ireland plant to South Korean company with large aspirations

The deal gave SK Holdings, which had 2016 revenues exceeding $120 billion, its start in contract manufacturing, a field it sees as feeding its growth. SK pointed out that the CDMO industry has been growing at about 16% the last several years, while AMPAC has racked up 15% annual growth.  


Suggested Articles

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.

Hansoh and Hengrui chiefs together make one of biopharma's richest families; prosecutors grill top Samsung exec; FDA cites another Aurobindo plant.

Turkey is getting its first locally produced mAb via an Iranian biosimilars marker and the $100 million plant it built there.